 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| Last Updated: Mar 13th, 2003 - 22:13:05 |
|
 |
Cardiac Risk Factor
Cardiac Risk Factor Low-Dose Doxycycline Lowers C-Reactive Protein in CAD Low-dose doxycycline reduced levels of C-reactive protein and other markers of inflammation in patients with coronary artery disease, Dr. David L. Brown said at the annual scientific sessions of the American Heart Association. Mar 13, 2003, 10:12pm Cardiac Risk Factor HDL Cholesterol: What Is Its True Clinical Significance? Although the cardioprotective effect of high-density lipoprotein cholesterol (HDL-C) has been recognized since 1950, research data on the long-term effects of treatments designed to raise serum HDL-C have only begun to emerge in the past two years. The authors explain how HDL-C fits into the pathogenesis of coronary heart disease and lay out a practical approach to the patient whose HDL-C may be too low. [ Visit Website ] Feb 9, 2003, 9:13pm Cardiac Risk Factor Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial N-3 polyunsaturated fatty acids (PUFAs) from oily fish protect against death from cardiovascular disease. We aimed to assess the hypothesis that incorporation of n-3 and n-6 PUFAs into advanced atherosclerotic plaques increases and decreases plaque stability, respectively. Feb 9, 2003, 8:55pm Cardiac Risk Factor AHA Endorses Fish Oil Supplements The AHA's new fish oil guidelines say patients with documented CHD ideally should get their daily fish oil fix from an approximately 3-ounce serving of a fatty fish such as salmon, herring, trout, or sardines. Somewhat leaner fish, such as canned tuna, halibut, and flounder also are fine but must be consumed in larger portions, according to the guidelines that were released in November (Circulation 106[21]:2747-57, 2002). Jan 30, 2003, 11:35pm Cardiac Risk Factor Optimal Diets for Prevention of Coronary Heart Disease JAMA Vol. 288 No. 20,November 27, 2002 Substantial evidence indicates that diets using nonhydrogenated unsaturated fats as the predominant form of dietary fat, whole grains as the main form of carbohydrates, an abundance of fruits and vegetables, and adequate omega-3 fatty acids can offer significant protection against CHD. Such diets, together with regular physical activity, avoidance of smoking, and maintenance of a healthy body weight, may prevent the majority of cardiovascular disease in Western populations. [ Visit Website ] Nov 29, 2002, 8:04am Cardiac Risk Factor B Vitamins and Restenosis Elevated plasma homocysteine is an independent risk factor for the development of coronary artery disease (CAD) and has previously been shown to correlate with outcomes in the presence of established CAD Oct 5, 2002, 9:11am Cardiac Risk Factor EBCT and evaluation of coronary artery calcium It is generally accepted that the presence of coronary calcium correlates directly with coronary atherosclerosis. Does the amount, however, as detected by electron-beam CT (EBCT) predict adverse events independently of traditional risk factors such as BP, cholesterol levels, smoking status, plasma glucose level, and age? Sep 28, 2002, 7:19pm Cardiac Risk Factor Dose Response of Almonds on Coronary Heart Disease Risk Factors: Dose Response of Almonds on Coronary Heart Disease Risk Factors: Blood Lipids, Oxidized Low-Density Lipoproteins, Lipoprotein(a), Homocysteine, and Pulmonary Nitric Oxide Sep 10, 2002, 9:25pm Cardiac Risk Factor Lipid-Lowering Therapy: What the New NCEP A specialist in cardiovascular preventive care explains how the new guidelines from the National Cholesterol Education Project have improved on previous versions, especially with respect to one of the primary care physician's biggest challenges: the patient with borderline levels of risk. Sep 6, 2002, 7:41am Cardiac Risk Factor Homocysteine-Lowering Therapy After Angioplasty In this report of clinical outcomes after additional follow-up through 1 year, Schnyder and colleagues found that the risk of major adverse clinical outcomes (death, nonfatal myocardial infarction, and need for repeat revascularization) was significantly lower among patients who had received 6 months of homocysteine-lowering therapy after coronary angioplasty than among patients who had received placebo. Aug 31, 2002, 11:18pm |
|
|
